Background: The Emerging Role of Gut Microbiome in Gynecologic Cancers
The human gut microbiome has emerged as a critical modulator of cancer treatment response, immune function, and patient outcomes across multiple malignancy types. In gynecologic oncology specifically, emerging evidence suggests that microbial composition may influence tumor progression, chemotherapy efficacy, and immunotherapy response in ovarian, endometrial, and cervical cancers. Despite this growing recognition, substantial barriers exist to integrating microbiome research into routine clinical practice, particularly regarding the logistics of non-invasive biospecimen collection.
Stool sample collection presents unique challenges in clinical research settings. Unlike blood or tissue specimens, stool samples require specific collection protocols, storage conditions, and patient compliance mechanisms. For gynecologic oncology patients who often experience significant symptom burden and treatment-related fatigue, adding research biospecimen collection to clinical workflows demands careful consideration of patient burden and operational feasibility.
Understanding these implementation challenges, researchers at a single institution conducted a prospective feasibility study to evaluate the integration of at-home stool biospecimen collection into routine gynecologic oncology care, seeking to establish real-world benchmarks for recruitment, compliance, and factors influencing patient participation.
Study Design and Methods
This prospective, single-institution investigation was conducted from March 2023 through April 2024, enrolling eligible gynecologic oncology patients at a major academic cancer center. The study employed a linked substudy design within the Total Cancer Care® protocol, a comprehensive research enrollment program that facilitates patient participation in multiple research initiatives.
Eligible participants included all patients receiving care within the gynecologic oncology service who were approached for Total Cancer Care enrollment. Those who consented to the main protocol were subsequently offered optional participation in the stool biospecimen substudy. Patients who agreed to participate received an at-home stool collection kit with detailed instructions for self-collection and sample return.
The study collected comprehensive clinical and demographic data through systematic abstraction from the electronic medical record. Primary endpoints included Total Cancer Care enrollment rates, stool kit acceptance among enrollees, and stool kit return rates among those who accepted the kit. Statistical analysis employed multivariable logistic regression to identify independent predictors of participation at each stage of the enrollment funnel.
Key Findings: Recruitment and Compliance Outcomes
The study enrolled 666 patients who were approached for participation, representing a comprehensive cohort of gynecologic oncology patients during the study period. Of these, 407 patients (61%) elected to enroll in Total Cancer Care, establishing a solid foundation for the linked biospecimen substudy. This enrollment rate demonstrates substantial patient willingness to engage in cancer research activities when appropriately offered within the clinical care setting.
Among Total Cancer Care enrollees, 234 patients (58%) accepted the optional stool biospecimen kit when offered. This acceptance rate indicates that while the majority of enrolled patients agreed to participate in some research activities, additional barriers existed for the specific biospecimen collection component. The researchers noted that kit offers occurred within routine clinical encounters, reflecting real-world implementation conditions.
Of the 234 patients who accepted a stool kit, 100 individuals (43%) ultimately returned a completed stool sample. This return rate among kit acceptors represents the critical compliance metric for practical implementation, as it reflects the proportion of patients who successfully navigated the at-home collection and return process.
Predictors of Participation: Multivariable Analysis Results
Multivariable logistic regression analysis identified significant predictors of participation at each enrollment stage. For Total Cancer Care enrollment, prior clinical trial participation emerged as the strongest independent predictor (p < 0.01), suggesting that patients with previous research experience demonstrated greater willingness to engage in additional research activities. The treating provider also significantly influenced enrollment rates (p < 0.05), indicating that provider-level variation in research discussion affected patient participation decisions.
For stool kit acceptance among Total Cancer Care enrollees, the treating provider demonstrated the most powerful association (p < 0.0001), substantially outweighing other demographic or clinical variables. This finding highlights that provider engagement and communication regarding the biospecimen substudy represented the dominant factor influencing whether patients accepted the collection kit. This result has important implications for implementation strategies, suggesting that provider training and engagement may yield the greatest returns for recruitment success.
Notably, no demographic or clinical variables reached statistical significance as predictors of kit return among those who had accepted the kit. This suggests that once patients committed to participation by accepting the kit, return rates were not substantially influenced by observable patient characteristics. The findings imply that return rates may be more dependent on logistics, kit design, and environmental factors rather than patient-level predictors.
Expert Commentary: Implications for Microbiome Research Infrastructure
The findings from this study carry significant implications for the future of microbiome-focused translational research in gynecologic oncology. First and foremost, the demonstration of feasibility establishes that at-home stool collection can be successfully integrated into routine cancer care without imposing prohibitive burden on clinical operations or patients. The 43% return rate, while leaving room for improvement, provides a realistic baseline for future program development and sample size calculations.
The dominant role of provider engagement in driving participation at multiple stages cannot be overstated. In an era of increasing recognition that patient outcomes are influenced by complex biological systems including the microbiome, establishing robust biospecimen collection infrastructure becomes essential. This study suggests that investment in provider education and engagement may represent the highest-yield strategy for optimizing research participation.
Several limitations merit consideration when interpreting these results. The single-institution design may limit generalizability to other practice settings with different patient populations or institutional cultures regarding research participation. The study period coincided with the post-pandemic era, which may have influenced patient attitudes toward research participation and healthcare engagement. Additionally, the study did not capture detailed reasons for kit non-return, which would inform targeted interventions to improve compliance.
The mechanistic rationale for gut microbiome research in gynecologic cancers remains compelling. Preclinical models have demonstrated bidirectional communication between gut microbial communities and tumor microenvironments, with specific bacterial species influencing inflammatory responses, immune checkpoint expression, and chemotherapy metabolism. Translating these findings to clinical applications requires large-scale biospecimen collection to establish reference ranges, identify microbiome signatures predictive of treatment response, and ultimately develop microbiome-directed therapeutic interventions.
Conclusion: Building Infrastructure for Translational Microbiome Science
This prospective feasibility study demonstrates that implementation of at-home stool biospecimen collection in gynecologic oncology is achievable within routine clinical care settings. With 61% patient enrollment in research protocols and 43% successful sample return, the study establishes practical benchmarks for program development and resource allocation.
The identification of provider engagement as the strongest determinant of participation across multiple endpoints represents a key actionable finding. Institutions seeking to develop microbiome research programs should prioritize provider training, standardize research discussions, and ensure that clinical workflows facilitate rather than impede biospecimen collection discussions.
As the field moves toward precision oncology approaches that incorporate multifactorial influences on treatment response, robust biospecimen infrastructure will become increasingly essential. The foundation established by this study provides a template for expanding microbiome-focused research in gynecologic cancers and potentially other malignancy types where gut microbial influences on outcomes are suspected.
Future research should focus on optimizing kit design and return logistics, implementing provider-focused interventions to enhance recruitment, and conducting qualitative investigations to understand barriers to compliance. With continued refinement of implementation strategies, stool biospecimen collection programs can support the translational science necessary to move microbiome discoveries from bench to bedside in gynecologic oncology practice.
Funding and Clinical Trials
This study was conducted as part of the Total Cancer Care® protocol. The authors report no conflicts of interest relevant to this research. Further information regarding study protocols and data availability may be obtained through the sponsoring institution.
References
1. Chalif J, Moruzzi C, Velasquez J, O’Connor R, Fulton J, Mehra Y, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O’Malley DM, Monovich L, Spakowicz DJ, Chambers LM. Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study. Gynecologic oncology. 2026-03-28;208:63-68. PMID: 41905324.
